The Pharmacy Nobody’s Heard Of, That Made Their Pain Reliever

The Company That Cures Your Allergies But Can’t Cure Its Perception

Morepen Laboratories is a 40-year-old pharmaceutical company headquartered in Gurgaon with manufacturing plants in Baddi, Himachal Pradesh. They make Active Pharmaceutical Ingredients (APIs), finished formulations, and medical devices. Think of them as the invisible hand that manufactures the drug that cures your hay fever. They probably did. Their portfolio includes 70% of India’s Montelukast market (the anti-asthma king), 69% of Loratadine (the allergy buster), and they’re not shy about it.

Financially, they’re at a crossroads. FY25 saw PAT of ₹118 crore with a 3% dividend after 23 years of financial celibacy. Nine months into FY26, they’ve already posted ₹66 crore PAT. But the stock is down 24% in 6 months, P/E is at 26.5x (above sector median of 27.5x), and investors are asking: “Why are you so expensive if you’re growing so slowly?” Fair question. Unfair answer: because three days ago, they bagged ₹825 crore in CDMO contracts from international players. Supplies start in 4-5 months. And literally nobody in the retail market knows this yet.

The Q3 FY26 story has two chapters. First: organic business challenges. API pricing is under pressure from Chinese competition. Margins are being squeezed. Growth is pedestrian at 3-13%. Second: a mega-contract win that could change the earnings trajectory. A ₹825 crore international CDMO order over 12-15 months could add 30-40% to quarterly revenue once it hits stride. The market hasn’t priced this in because investors were too busy selling.

They Make The Molecules That Stop You From Sneezing at 3 AM

Morepen operates in three vertical silos: APIs (70% of pharma business), Finished Formulations & OTC (25% of pharma business), and Medical Devices (30% of total company revenue). They’re not a one-trick pony; they’re a three-trick horse that’s exceptionally good at tricks 1 and 3, and mediocre at trick 2.

The API Business: They buy raw materials, synthesize active pharmaceutical ingredients, and sell them to formulators worldwide. They’ve added 80+ new customers in H1 FY25 and export to 80+ countries. The dominant products—Loratadine, Desloratadine, Montelukast, Atorvastatin—are what the entire world allergic to ragweed depends on. But here’s the problem: they’re also what the entire world’s Chinese manufacturers have learned to make cheaper. Over the past two years, average realisations per kg have fallen 24%. Loratadine, Montelukast, and Desloratadine together contribute 45-60% of API revenue, yet prices are under relentless downward pressure. The company is shifting to higher-margin Western markets (Europe + USA now at 38% of API sales vs 27% in FY22). Good strategy. Slow execution.

The Finished Formulations & OTC Business: They make branded drugs under Morepen brand and OTC products under the Dr. Morepen brand (Burnol for burns, Lemolate for cough). This segment grew 11% QoQ in Q3 but contributes only 25% of pharma revenue. It’s profitable but unglamorous.

Medical Devices: Glucometers, BP monitors, thermometers. They’ve sold 16.85 million glucometers cumulatively. Q3 medical device revenue was ₹177 crore, up 44% YoY. This is the growth star. Glucometers alone contributed 76% of device revenue. They’re scaling production capacity—200 lakh units annually for glucometers, 9 lakh units for BP monitors. This business is 30% of company revenue and growing at double digits. Call it the future.

Q3 FY26: The Earnings Tango That Won’t Dance